▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Kiadis Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.55.
The current consensus among 3 contributing investment analysts is to hold stock in Kiadis Pharma. This rating has held steady since June 2020, when it changed from a Buy consensus rating.
Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.